02698nas a2200409   4500000000100000008004100001260001300042653000900055653002200064653002200086653001200108653002200120653001800142653003800160653001100198653001100209653001200220653000900232653003200241653001600273653001000289653001500299653004700314653001300361100001700374700002100391700002100412700001200433700001000445700001300455245008500468856006900553300001200622490000700634520163300641022001402274       2002                            d  c2002 Dec10aAged10aAged, 80 and over10aAntifungal Agents10aCandida10aCandidiasis, Oral10aCarrier State10aDrug Resistance, Multiple, Fungal10aFemale10aHumans10aleprosy10aMale10aMicrobial Sensitivity Tests10aMiddle Aged10aMouth10aPrevalence10aRandom Amplified Polymorphic DNA Technique10aThailand1 aReichart P A1 aSamaranayake L P1 aSamaranayake Y H1 aGrote M1 aPow E1 aCheung B00aHigh oral prevalence of Candida krusei in leprosy patients in northern Thailand.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC154582/pdf/0117.pdf  a4479-850 v403 a<p>Although Candida albicans is the most common human yeast pathogen, other Candida species such as C. krusei are now recognized as emerging agents, especially in patients with human immunodeficiency virus (HIV) disease. C. krusei is inherently resistant to the widely used triazole antifungal fluconazole and poses therapeutic problems, especially in systemic candidiasis. In a surveillance study of leprosy patients (with arrested or burnt-out disease) in a leprosarium in northern Thailand, we found a rate of oral carriage of C. krusei (36%) significantly (P < 0.05) higher than that for a healthy control group (10%). Among the Candida-positive patients, 16 of 35 (46%) carried C. krusei, while C. albicans was the second most common isolate (12 of 35 patients; 34%). The corresponding figures for the control group were 2 of 13 (15%) and 6 of 13 (46%), respectively. Studies of the antifungal resistance of the C. krusei isolates from patients indicated that all except one of the isolates were resistant to fluconazole, two isolates were resistant to ketoconazole, and all isolates were sensitive to amphotericin B. Evaluation of their genetic profiles by randomly amplified polymorphic DNA analysis with three different primers and subsequent analysis of the gel profiles by computerized cluster-derived dendrograms revealed that the C. krusei isolates from patients belonged to 10 disparate clusters, despite the origin from a single locale. These nascent findings indicate an alarmingly high prevalence of a Candida species resistant to a widely used antifungal in a part of the world where HIV disease is endemic.</p>  a0095-1137